On This Day in Health: May 13, 2022
On May 13, 2022, the U.S. Food and Drug Administration approved tirzepatide, marketed as Mounjaro, to improve blood sugar control in adults with type 2 diabetes. The original approval specified use alongside diet and exercise. The medicine was notable for activating two hormone receptors involved in glucose regulation: glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1. Combining those activities in one treatment marked a new approach within diabetes pharmacology. The event should be remembered for its initial indication, rather than being retroactively described as an approval for weight management or every later use of tirzepatide.
Type 2 diabetes develops when the body does not make or use insulin adequately, allowing blood glucose to remain too high. Treatment often requires several complementary measures, and existing medicines do not help every patient reach their goals. Tirzepatide's dual receptor activity offered another way to influence the systems involved in blood sugar control. The product was given by injection under the skin once a week, with adjustment according to tolerability and treatment needs. It was not insulin, and its availability did not remove the need to monitor diabetes or consider other components of care. A new pharmacological option entered an already complex pattern of long-term disease management.
The supporting program included randomized trials comparing tirzepatide with placebo and other diabetes therapies. Researchers assessed changes in hemoglobin A1c, a measure reflecting blood sugar control over time, and collected safety information across a wider set of studies. The FDA's trial snapshot described nine trials in the original review, five of which assessed efficacy. Benefits had to be considered alongside adverse effects and restrictions. Gastrointestinal symptoms were important tolerability issues, and the prescribing information included warnings about thyroid C-cell tumors observed in animals. Such findings did not prove the same effect in humans, but they required precautions and clear communication about who should avoid the medicine.
The May 13 approval helped show how knowledge of metabolic signaling could produce a treatment that acted through more than one receptor. Its importance was not simply the addition of another product name to the pharmacy shelf. It expanded the choices available when clinicians and patients were working to improve glucose control, while preserving the need for individualized assessment. Later attention to weight change and additional indications made the drug widely discussed, but those developments should not blur the original regulatory event. The anniversary records a diabetes treatment milestone in 2022, with the benefits, limitations and monitoring responsibilities that accompany a new medicine intended for continuing use.
The original approval concerned adults with type 2 diabetes.
Tirzepatide activates both GIP and GLP-1 receptors.
It was authorized as an addition to diet and exercise.
The product was administered by a weekly injection under the skin.
The trial program assessed glucose control and safety across several studies.
Later uses of tirzepatide are separate from its May 2022 diabetes approval.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.